论文部分内容阅读
目的观察噻托溴铵与舒利迭联合应用对稳定期慢性阻塞性肺疾病(COPD)患者肺功能及生活质量的影响。方法 70例稳定期COPD患者,随机分为观察组(35例)和对照组(35例),对照组仅吸入舒利迭(沙美特罗/氟替卡松)50/250μg,2次/d,观察组给予噻托溴铵与舒利迭联合治疗,吸入舒利迭50/250μg,2次/d,吸入噻托溴铵18μg,1次/d,治疗前、治疗后2周采用肺功能检测仪监测肺功能指标(第1秒用力呼气容积FEV1、用力肺活量FVC、深吸气量IC),采用圣·乔治呼吸问卷(SGRQ)评价患者生活质量改善情况。结果两组治疗2周后FEV1、FVC、IC较治疗前明显升高(P<0.05),SGRQ评分明显低于治疗前(P<0.05),观察组治疗2周后FEV1、FVC、IC明显高于对照组(P<0.05),SGRQ评分明显低于对照组,(P<0.05)。结论噻托溴铵与舒利迭联合疗法能够改善稳定期COPD的肺功能,提高生活质量,值得临床推广使用。
Objective To observe the effects of combination of tiotropium and seretide on pulmonary function and quality of life in patients with stable chronic obstructive pulmonary disease (COPD). Methods Seventy patients with stable COPD were randomly divided into observation group (35 cases) and control group (35 cases). In the control group, only 50/50 μg of salmeterol / fluticasone was administered to the control group. The observation group Administered tiotropium and seretide combination therapy, inhalation of seretide 50 / 250μg, 2 times / d, inhalation of tiotropium 18μg, 1 / d, before treatment, 2 weeks after treatment with pulmonary function monitor (FEV1, forced vital capacity FVC and deep inspiration IC), and the SGRQ was used to evaluate the quality of life of the patients. Results After 2 weeks of treatment, the FEV1, FVC and IC of the two groups were significantly higher than those before treatment (P <0.05), and the SGRQ scores were significantly lower than those before treatment (P <0.05). The FEV1, FVC and IC of the observation group were significantly higher In the control group (P <0.05), the SGRQ score was significantly lower than that in the control group (P <0.05). Conclusion The combination of tiotropium and seretide can improve lung function and improve quality of life in patients with stable COPD. It is worthy of clinical application.